Buy Atomoxetine (Strattera) pills online

How and where to order Strattera (Atomoxetine Hydrochloride) 10 mg, 18 mg, 25 mg, 40 mg, 60 mg capsules or tablets online:

Shop:PHARMA SHOP - 5% discount coupon hf-5478
Prices:from $0.51 per pill
Forms:10, 18, 25, 40, 60 mg pills
Quantity:30-360 tablets and capsules
Type:Atomoxetine brand, Strattera generic
Payment:Visa, Mastercard, AmEx, Cryptocurrencies
Delivery:Regular and express mail service
Shipping:Worldwide, including USA, UK, Europe, Canada, Australia

Indications and usage:

Strattera (Atomoxetine Hydrochloride) is a selective norepinephrine reuptake inhibitor indicated for the treatment of:

  • attention-deficit/hyperactivity disorder (ADHD)
  • major depression
  • fibromyalgia
  • social anxiety disorder

    Dosage and administration:

    Initial, target and maximum daily dose for acute and maintenance/extended treatment:

    Body weight Initial daily dose Target total daily dose Maximum total daily dose
    Children and adolescents up to 70 kg 0.5 mg/kg 1.2 mg/kg 1.4 mg/kg
    Children and adolescents over 70kg and adults 40 mg 80 mg 100 mg

    Dosing adjustment - hepatic impairment, strong CYP2D6 inhibitor, and in patients known to be CYP2D6 poor metabolizers (PMs).

    Dosage forms and strengths:

    Each Strattera capsule contains Atomoxetine Hydrochloride equivalent to 10, 18, 25, 40, 60, 80, or 100 mg of Atomoxetine.


  • Hypersensitivity to atomoxetine or other constituents of product.
  • Strattera use within 2 weeks after discontinuing MAOI or other drugs that affect brain monoamine concentrations.
  • Narrow angle glaucoma.
  • Pheochromocytoma or history of pheochromocytoma.
  • Severe cardiovascular disorders that might deteriorate with clinically important increases in HR and BP.

    Warnings and precautions:

  • Suicidal ideation: monitor for suicidality, clinical worsening, and unusual changes in behavior.
  • Severe liver injury: should be discontinued and not restarted in patients with jaundice or laboratory evidence of liver injury.
  • Serious cardiovascular events: sudden death, stroke and myocardial infarction have been reported in association with atomoxetine treatment. Patients should have a careful history and physical exam to assess for presence of cardiovascular disease. Strattera generally should not be used in children or adolescents with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that may place them at increased vulnerability to its noradrenergic effects. Consideration should be given to not using Strattera in adults with clinically significant cardiac abnormalities.
  • Emergent cardiovascular symptoms: patients should undergo prompt cardiac evaluation.
  • Effects on blood pressure and heart rate: increase in blood pressure and heart rate; orthostasis and syncope may occur. Use with caution in patients with hypertension, tachycardia, or cardiovascular or cerebrovascular disease.
  • Emergent psychotic or manic symptoms: consider discontinuing treatment if such new symptoms occur.
  • Bipolar disorder: screen patients to avoid possible induction of a mixed/manic episode.
  • Aggressive behavior or hostility shouldbe monitored.
  • Possible allergic reactions, including anaphylactic reactions, angioneurotic edema, urticaria, and rash.
  • Effects on urine outflow: urinary hesitancy and retention may occur.
  • Priapism: prompt medical attention is required in the event of suspected priapism.
  • Growth: height and weight should be monitored in pediatric patients.
  • Concomitant use of potent CYP2D6 inhibitors or use in patients known to be CYP2D6 PMs: dose adjustment of Strattera may be necessary.


    Human experience

    No fatal overdoses occurred in clinical trials with atomoxetine. There is limited clinical trial experience with Strattera overdose. During postmarketing, there have been fatalities reported involving a mixed ingestion overdose of this medication and at least one other drug. There have been no reports of death involving overdose of atomoxetine alone, including intentional overdoses at amounts up to 1400 mg. In some cases of overdose involving Strattera, seizures have been reported. The most commonly reported symptoms accompanying acute and chronic overdoses of this drug were somnolence, agitation, hyperactivity, abnormal behavior, and gastrointestinal symptoms. Signs and symptoms consistent with mild to moderate sympathetic nervous system activation (e.g., mydriasis, tachycardia, dry mouth) have also been observed. Less commonly, there have been reports of QT prolongation and mental changes, including disorientation and hallucinations.

    Management of overdose

    An airway should be established. Monitoring of cardiac and vital signs is recommended, along with appropriate symptomatic and supportive measures. Gastric lavage may be indicated if performed soon after ingestion. Activated charcoal may be useful in limiting absorption. Because Strattera (Atomoxetine) is highly protein-bound, dialysis is not likely to be useful in the treatment of overdose.

    Adverse reactions, side effects:

    Most common side effects of atomoxetine pills ( >= 5% and at least twice the incidence of placebo patients):

  • Child and adolescent clinical trials: nausea, vomiting, fatigue, decreased appetite, abdominal pain, and somnolence.
  • Adult clinical trials: constipation, dry mouth, nausea, decreased appetite, dizziness, erectile dysfunction, and urinary hesitation.

    To report suspected adverse reactions of Strattera (Atomoxetine HCl) capsules, contact Eli Lilly pharmaceutical company or your local FDA.

    Drug interactions:

  • Monoamine oxidase inhibitors.
  • CYP2D6 inhibitors: concomitant use may increase atomoxetine steady-state plasma concentrations in EMs.
  • Antihypertensive drugs and pressor agents: possible effects on blood pressure.
  • Albuterol (or other beta-2 agonists): action of albuterol (salbutamol) on cardiovascular system can bepotentiated.

    Use in specific populations:

  • Pregnancy and lactation: pregnant or nursing women should not use unless potential benefit justifies potential risk to fetus or infant.
  • Hepatic insufficiency: increased exposure (AUC) to atomoxetine than with normal subjects in EM subjects with moderate (Child-Pugh Class B) (2-fold increase) and severe (Child-Pugh Class C) (4-fold increase).
  • Renal insufficiency: higher systemic exposure to atomoxetine than healthy subjects for EM subjects with end stage renal disease - no difference when exposure corrected for mg/kg dose.
  • Patients with concomitant illness: does not worsen tics in patients with ADHD and comorbid Tourette's disorder.
  • Patients with concomitant illness: does not worsen anxiety in patients with ADHD and comorbid anxiety disorders.

    Where to buy atomoxetine online:

    To purchase Strattera (Atomoxetine HCl) 10, 18, 25, 40, 60 mg pills from reliable online pharmacies and drugstores at low prices please use resources described above on this webpage.